Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.45 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069631 | 0.73 | CRHR1 (0.47) | CRHR1DPP4 | |
| SCHEMBL6070559 | 0.71 | CRHR1 (0.55) | CRHR1DPP4 | |
| SCHEMBL6070464 | 0.71 | CRH (0.59) | CRHR1 | |
| SCHEMBL1924189 | 0.70 | CRHR1 (0.42) | CRHR1DPP4HSD11B1DPP8USP2 | |
| SCHEMBL6070921 | 0.69 | CRHR1 (0.43) | CRHR1HSD11B1 | |
| SCHEMBL1943591 | 0.69 | EGLN2 (0.49) | CRHR1HSD11B1USP2ALDH1A1HPGD | |
| SCHEMBL3609043 | 0.69 | HSP90AA1 (0.48) | CRHR1DPP4HSD11B1DPP8USP2 | |
| SCHEMBL6498648 | 0.68 | SHMT1 (0.38) | DPP4NPC1 | |
| SCHEMBL22686367 | 0.67 | PDE10A (0.44) | CRHR1NPC1 | |
| SCHEMBL3605062 | 0.67 | HSP90AA1 (0.46) | DPP4HSD11B1DPP8USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026317-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6960583-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885DPP4 1682/4885HSD11B1 398/4885 |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885DPP4 1682/4885HSD11B1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.